SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Infinity Pharmaceuticals
INFI 0.0160-4.8%Sep 29 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (44)7/4/2006 9:42:29 PM
From: Mike McFarland   of 210
 
Bauer and Fletcher presented a preclinical evaluation of IPI-504 in GIST cell lines at the joint National Cancer Institute-American Association of Cancer Researchers-European Organization for Research and Treatment of Cancer meeting on targeted therapies held Nov. 14-18 in Philadelphia, PA, showing that IPI-504 is as effective as 17-AAG at shutting down Gleevec-resistant GIST.

liferaftgroup.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News